TCGA-85-A4QQ-01A-41R-A262-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.390
- G2M_CHECKPOINT+0.270
- P53_PATHWAY+0.260
- E2F_TARGETS+0.250
- MYC_TARGETS_V2+0.230
- WNT_BETA_CATENIN_SIGNALING+0.220
- APICAL_SURFACE+0.200
- CHOLESTEROL_HOMEOSTASIS+0.160
- ESTROGEN_RESPONSE_LATE+0.160
- MYC_TARGETS_V1+0.160
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.420
- INTERFERON_GAMMA_RESPONSE-0.400
- ALLOGRAFT_REJECTION-0.320
- KRAS_SIGNALING_UP-0.240
- BILE_ACID_METABOLISM-0.230
- IL2_STAT5_SIGNALING-0.230
- IL6_JAK_STAT3_SIGNALING-0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.230
- FATTY_ACID_METABOLISM-0.220
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-8479-01A-11R-2326-07 | — | cohortSQ1 | 0.814 |
| 2 | SRR8613740 | — | E | 0.796 |
| 3 | SRR8613771 | — | E | 0.787 |
| 4 | SRR650136 | — | — | 0.778 |
| 5 | SRR6013543 | — | cohortSQ1 | 0.761 |
| 6 | TCGA-77-8153-01A-11R-2403-07 | — | cohortSQ2 | 0.734 |
| 7 | SRR8518327 | — | E | 0.732 |
| 8 | TCGA-DK-A3IM-01A-11R-A20F-07 | — | — | 0.732 |
| 9 | SRR8518192 | — | E | 0.722 |
| 10 | TCGA-77-A5G3-01A-31R-A27Q-07 | — | cohortSQ2 | 0.721 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.390 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.080 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.070 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.060 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |